Pfizer Stock Slips 4.07% in Three Days Amid Federal Probe, Trading Volume Ranks 46th

On March 26, 2025, Pfizer (PFE) experienced a decline of 1.33%, marking its third consecutive day of losses, with a total decrease of 4.07% over the past three days. The trading volume for the day was 12.51 billion, ranking 46th in the overall market.

Pfizer is currently under federal investigation for allegations that it delayed the announcement of its 2020 COVID-19 vaccine success for political reasons. This probe has raised concerns about the company's transparency and ethical practices, potentially impacting investor confidence.

The investigation, reported by The Wall Street Journal, has led to a slip in Pfizer's stock price. The U.S. attorney's office in Manhattan has initiated an inquiry into whether the pharmaceutical giant intentionally delayed sharing positive results about its COVID-19 vaccine. This development has added to the market's uncertainty surrounding Pfizer's future performance.

Pfizer's shares reached a session low following the reports, with U.S. prosecutors looking into a tip that alleges the company delayed announcing the success of its COVID-19 vaccine. The investigation is focused on the timing of the vaccine's success announcement, which has raised questions about the company's motives and the potential impact on public health.